scholarly journals Severe ulcerative proctitis, pyoderma gangrenosum, hidradenitis suppurativa and fever in a patient with a rare variant of the PSTPIP1 gene

Author(s):  
N. Hieta ◽  
H. Nuutinen ◽  
J. Roivas ◽  
K. Salminen ◽  
H. Kujari ◽  
...  

2013 ◽  
Vol 31 (1) ◽  
pp. e20-e21 ◽  
Author(s):  
Misha V. Koshelev ◽  
Paige A. Garrison ◽  
Teresa S. Wright


2017 ◽  
Vol 178 (1) ◽  
Author(s):  
H. Sonbol ◽  
S. Duchatelet ◽  
S. Miskinyte ◽  
B. Bonsang ◽  
A. Hovnanian ◽  
...  


2017 ◽  
Vol 3 (1) ◽  
pp. 70-73 ◽  
Author(s):  
Dorene Niv ◽  
James A. Ramirez ◽  
David P. Fivenson


2001 ◽  
Vol 5 (3) ◽  
pp. 223-227 ◽  
Author(s):  
Anthony J. Papadopoulos ◽  
Robert A. Schwartz ◽  
Rajendra Kapila ◽  
Joseph A. Samady ◽  
Zbigniew Ruszczak ◽  
...  

Background: Pyoderma vegetans is a rare condition that is clinically characterized by large verrucous plaques with elevated borders and multiple pustules. The etiology of this disorder remains unknown. Objectives: We describe a 24-year-old woman with rapidly evolving pyoderma vegetans. Our patient had the unique additional findings of a highly elevated serum IgE level and a history of hidradenitis suppurativa. Conclusions: Pyoderma vegetans is diagnosed on clinical and histological criteria. Differentiation must be made from disorders such as pyoderma gangrenosum, Sweet's syndrome, and deep fungal infections. We illustrate a case of pyoderma vegetans and review the literature on this rare disorder. Clinical and histological criteria for diagnosis are presented, as well as differentiation from some mimicking disorders.



Dermatology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Alison H. Kohn ◽  
Afsaneh Alavi ◽  
April W. Armstrong ◽  
Folawiyo Babalola ◽  
Amit Garg ◽  
...  

<b><i>Background:</i></b> The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. <b><i>Summary:</i></b> Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23–24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. <b><i>Key Messages:</i></b> In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.



2015 ◽  
Vol 23 (3) ◽  
pp. 313-317
Author(s):  
Zehra AŞİRAN SERDAR ◽  
Şirin PEKCAN YAŞAR ◽  
Yeşim DOĞAN SABUNCUOĞLU ◽  
Pembegül GÜNEŞ


Author(s):  
D. Mintoff ◽  
S. M. Vella ◽  
M. Ceci ◽  
A. Portelli ◽  
A. Savic ◽  
...  




2010 ◽  
Vol 101 (8) ◽  
pp. 717-721
Author(s):  
A.E. García-Rabasco ◽  
A. Esteve-Martínez ◽  
V. Zaragoza-Ninet ◽  
J.L. Sánchez-Carazo ◽  
V. Alegre-de-Miquel


Sign in / Sign up

Export Citation Format

Share Document